Opendata, web and dolomites

SPELITEC SIGNED

Sequence sPecific ELImination of shiga-Toxin E. Coli

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPELITEC project word cloud

Explore the words cloud of the SPELITEC project. It provides you a very rough idea of what is the project "SPELITEC" about.

progression    individualised    toxins    patient    therapeutic    coli    stec    hospitalized    disrupting    safe    coupled    treatment    resistance    license    batch    orally    solid    tests    drug    microbiota    complications    bacteria    alternative    initiate    designed    multinational    validation    bacterial    primary    mechanism    dialysis    gel    antibiotic    eliminates    young    antibodies    spelitec    safety    selectively    spectrum    mutation    symptomatic    uremic    pharmacological    authorization    first    variants    empts    liquid    orphan    compound    children    validate    populations    elimination    clinical    strains    infections    team    nature    rehydration    model    pharma    eligo    companies    exert    eb003    administered    disease    transfusions    consisting    multivalent    haemolytic    market    medical    unmet    indication    stecs    release    inducing    preclinical    finalise    launch    fatal    company    shiga       toxin    toxicity    healthy    producing    mix    treatments    business    validated    acquisition    animals    background    plans    capsid    receptors    action    conducting    receive    paediatric    clinically    patients    humans    complete   

Project "SPELITEC" data sheet

The following table provides information about the project.

Coordinator
ELIGO BIOSCIENCE 

Organization address
address: 29 RUE FAUBOURG SAINT JACQUES PEPIN
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙948˙250 €
 EC max contribution 2˙763˙775 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELIGO BIOSCIENCE FR (PARIS) coordinator 2˙763˙775.00

Map

 Project objective

SPELITEC is the first treatment for Shiga toxin-producing E. coli (STEC) infections, which affects primary young children and can be fatal in 1-5% of the cases. Currently there is no validated safe treatment: hospitalized patients receive only symptomatic treatments consisting of rehydration coupled with transfusions and dialysis for haemolytic uremic complications. The SPELITEC program is designed to finalise preclinical and initiate clinical studies for elimination of STEC bacteria (Shiga-toxin producing E. coli) in paediatric populations with a dedicated product: EB003. EB003 selectively eliminates STEC bacteria early in the disease progression; it is not expected to exert any toxicity in humans or animals; it is a multivalent mix of different capsid variants allows to target the whole spectrum of clinically relevant strains and pre-empts the acquisition of resistance through mutation of bacterial receptors; it is administered orally by a liquid/gel which is patient-friendly and adapted to young children and it represents a cost-effective alternative to antibodies against Shiga toxins. Our technology is the only one allowing the specific elimination of STECs without toxin release and without disrupting microbiota and inducing antibiotic resistance. Eligo will complete early drug development, which should ensure market authorization given the orphan and unmet medical need nature of the indication, and plans to out-license the compound to an established pharma company that will launch the product on the market. The management team of Eligo has solid business and technical management experience in multinational companies and a very strong drug development background. During the Phase 2 project we will validate this new individualised therapeutic approach and mechanism of action by conducting the validation of the pharmacological model, the production of a clinical batch and the safety tests in healthy animals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPELITEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPELITEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More